Tenderwize
Retour à la recherche

Non-exclusive drug discount agreement for Tapentadol

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Jul 31, 2027 · 337 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Tapentadol (ATC-Code nach WHO: N02AX06)

50/100

Score d'opportunité

Needs reviewLow complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

50 / 100

Complexité

30 / 100

Facteurs de risque

No minimum or guaranteed quantities; actual demand is uncertain and may be low.

The buyer may terminate open-house if exclusive agreements are concluded (typical after 8-12 months).

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Jul 2027
  • Non-exclusive discount agreement for Tapentadol (ATC N02AX06) film tablets
  • Supply of pharmaceutical products under German statutory health insurance rebate system
Afficher le résumé complet

This is a non-exclusive drug discount agreement (Rabattvereinbarung) under German law §130a Abs.8 SGB V for the active substance Tapentadol (ATC N02AX06) in film-coated tablet form. The procedure is an open-house model open to all qualified pharmaceutical companies. There is no exclusivity, no guaranteed minimum purchase quantities, and no estimated value provided. The contract runs until 31 July 2027. Submission is electronic via DTVP, and confidentiality of the tender documents is required.

Risques

No minimum or guaranteed quantities; actual demand is uncertain and may be low.

The buyer may terminate open-house if exclusive agreements are concluded (typical after 8-12 months).

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Must be a pharmaceutical company (pharmazeutischer Unternehmer) as defined in §4 Abs.18 AMG for the offered products

Eligibility

  • Must submit declaration of no exclusion grounds (§§123,124 GWB)

Administrative

  • Must submit declaration regarding EU sanctions against Russia (Regulation 833/2014)

Les exigences peuvent être incomplètes.

Acheteur

Localisation

Erfurt, DEU

Profil acheteur

Ouvrir le profil

Identifiant

DE256878834

Activité

Health

Lots (1)

LOT-0001

Non-exclusive drug discount agreement for Tapentadol

Single lot for non-exclusive discount agreement for Tapentadol film tablets. Open to all qualified pharmaceutical companies. No guaranteed volumes.

SuppliesFrameworkEU fundedElectronic submission

Localisation

Dresden, Germany

Durée

Jun 2025 - Jul 2027

Catégorie

Pharmaceutical products

Date limite

Deadline Jul 31, 2027

Détails de la procédure

Date de publication
29 May 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
349702-2025

Documents (1)

Document de consultation 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30